- Home
- AUID vs ACET Comparison
AUID vs ACET Comparison
Compare AUID & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- ACET
- Stock Information
- Founded
- AUID 2009
- ACET 1947
- Country
- AUID United States
- ACET United States
- Employees
- AUID N/A
- ACET N/A
- Industry
- AUID Computer Software: Prepackaged Software
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- ACET Health Care
- Exchange
- AUID Nasdaq
- ACET Nasdaq
- Market Cap
- AUID 74.1M
- ACET 61.2M
- IPO Year
- AUID N/A
- ACET N/A
- Fundamental
- Price
- AUID $3.78
- ACET $0.77
- Analyst Decision
- AUID
- ACET Strong Buy
- Analyst Count
- AUID 0
- ACET 7
- Target Price
- AUID N/A
- ACET $5.60
- AVG Volume (30 Days)
- AUID 92.5K
- ACET 386.5K
- Earning Date
- AUID 08-07-2025
- ACET 08-12-2025
- Dividend Yield
- AUID N/A
- ACET N/A
- EPS Growth
- AUID N/A
- ACET N/A
- EPS
- AUID N/A
- ACET N/A
- Revenue
- AUID $1,025,363.00
- ACET N/A
- Revenue This Year
- AUID N/A
- ACET N/A
- Revenue Next Year
- AUID N/A
- ACET N/A
- P/E Ratio
- AUID N/A
- ACET N/A
- Revenue Growth
- AUID 230.96
- ACET N/A
- 52 Week Low
- AUID $3.68
- ACET $0.45
- 52 Week High
- AUID $10.21
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- AUID 35.65
- ACET 56.37
- Support Level
- AUID $3.83
- ACET $0.75
- Resistance Level
- AUID $4.20
- ACET $0.82
- Average True Range (ATR)
- AUID 0.38
- ACET 0.05
- MACD
- AUID -0.02
- ACET 0.01
- Stochastic Oscillator
- AUID 5.85
- ACET 71.64
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.